Stem Cell Therapy Market 2019 | Estimated Growth by Players Novartis AG, GlaxoSmithKline Plc., MEDIPOST Co., Ltd., Anterogen Co., Ltd. Pharmicell Co., Ltd. Holostem Terapie Avanzate S.r.l. JCR Pharmaceuticals Co., Ltd. NuVasive, Inc. RTI Surgical, Inc

Stem cells are products derived from the human body. Stem cell therapy is also known as regenerative medicine. Regenerative medicine refers to a group of biomedical approaches (such as tissue engineering) to stem cell therapies. These therapies have the ability to regenerate human cells, tissues, or organs, in order to restore normal functioning of the body. Stem cell therapies are used for treatment and improvement of disease such as spinal cord injury, Parkinson’s disease, sickle cell disease, diabetes, and heart disease.

Free Request Sample Copy of This Report: https://www.coherentmarketinsights.com/insight/request-sample/2848

Increasing research and development activities are one of major factors driving growth of the stem cell therapy market. For instance, in January 2010, the Augusta University (U.S) initiated Phase I clinical trial to evaluate the safety and effectiveness of a single, autologous cord blood stem infusion for treatment of cerebral palsy in children. The study is estimated to complete in July 2019. Cerebral palsy is a severe, lifelong disability disease that affects children, and has various signs and symptoms such as poor coordination, stiff muscles, and tremors.

Moreover, increasing product launches by key players is expected to boost demand for stem cell therapy over the forecast period. For instance, in March 2017, Osiris Therapeutics, Inc., launched their product called Prestige Lyotechnology for long-term storage of living cells and tissues. Prestige Lyotechnology mainly focuses on placental products such as stem cells. Such technological advancements are expected to support the growth of the stem cell therapy market.

Request Customization Report @ https://www.coherentmarketinsights.com/insight/request-customization/2848

For instance, in February 2018, City of Hope Medical Center, U.S initiated clinical phase I study of the pre-transplant immunosuppressive therapy for haploidentical transplants in patients with sickle cell disease. The study is expected to complete in February 2023.

Moreover, Europe is expected to gain significant share in the global stem cell therapy market over the forecast period, owing to increasing number of approvals by regulatory authorities in the region. For instance, in November 2018, Novartis AG received an approval from the European Commission for its CAR-T (Kymriah) for treatment of B-cell acute lymphoblastic leukemia in pediatric and adult patients.

For instance, in March 2019, the Chinese Academy of Sciences (CAS) announced the launch of three stem cell clinic research programs for treatment of severe eye diseases and gynecological diseases. The program is registered by the National Health Commission and the National Medical Products Administration. The stem cell research programs are majorly focused on treatment of retinal pigment degeneration, ovarian dysfunction, and intrauterine adhesions in women.

Key players operating in the stem cell therapy market include, Osiris Therapeutics, Inc. Novartis AG, GlaxoSmithKline Plc., MEDIPOST Co., Ltd., Anterogen Co., Ltd. Pharmicell Co., Ltd. Holostem Terapie Avanzate S.r.l. JCR Pharmaceuticals Co., Ltd. NuVasive, Inc. RTI Surgical, Inc., and Fibrocell Science, Inc.

Purchase Copy of This Business Research Report: https://www.coherentmarketinsights.com/market-insight/stem-cell-therapy-market-2848

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

About Us:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.